Jennifer Lynne Fox - 11 Jul 2024 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship: EVP, Ext Aff, GC, Corp Sec
Issuer ticker: EBS
Reported as of: 11 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jul 2024, 16:33:12 UTC
Prior SEC filing: 11 Jun 2024
Next SEC filing: 03 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Lynne Fox

Key filing fact

Jennifer Lynne Fox filed Form 4 for Emergent BioSolutions Inc. (EBS) on 12 Jul 2024.

Key facts

This page summarizes Jennifer Lynne Fox's Form 4 filing for Emergent BioSolutions Inc. (EBS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jul 2024, 16:33.

Change

Previous filing in this sequence was filed on 11 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Award

Transaction value: $0
Shares: +15,000
Change %: +8.8%
Price: $0.000000
Shares after: 186,382
Date: 11 Jul 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of restricted stock units granted under the company's Amended and Restated Stock Incentive Plan. These restricted stock units vest in one installment on the first anniversary of the date of grant assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.